IP Library Granted Patent US 8,709,426
Granted Patent B2
US 8,709,426 · App. 11/867,862 · Granted Apr 29, 2014

Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

Inventors: Thierry Hercend (Nogent-sur-Marne, FR); Frederic Triebel (Neuilly-sur-Seine, FR); Sergio Roman-Roman (Paris, FR); Laurent Ferradini (Paris, FR)
Assignee: Aventis Pharma S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,426
App. No.
11/867,862
Granted
Apr 29, 2014
Kind
B2
Abstract

The present invention relates to new nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.

Claims (15)

1. An isolated antibody, or an antigen binding fragment thereof, directed against an antigenic determinant of a Vβ peptide encoded by a nucleic acid sequence selected from the group consisting of:

nucleotides 54 to 395 of SEQ ID NO: 3,

nucleotides 18 to 329 of SEQ ID NO: 4, and

nucleotides 28 to 366 of SEQ ID NO: 5,

wherein the antibody, or antigen binding fragment thereof, specifically binds to the Vβ peptide.

2. The antibody or an antigen binding fragment of claim 1 , which is a monoclonal antibody or an antigen binding fragment thereof.

3. The antigen binding fragment of claim 2 , wherein the fragment is selected from the group consisting of a Fab fragment, a Fab′ fragment, and a (Fab′) 2 fragment.

4. A diagnostic composition comprising the monoclonal antibody of claim 2 .

5. A diagnostic composition comprising the antigen binding fragment of claim 3 .

6. A therapeutic composition comprising the monoclonal antibody of claim 2 .

7. A therapeutic composition comprising the antigen binding fragment of claim 3 .

8. The therapeutic composition of claim 6 , wherein the composition further comprises a cytotoxic molecule or a radio-isotope.

9. The therapeutic composition of claim 7 , wherein the composition further comprises a cytotoxic molecule or a radio-isotope.

10. A composition comprising the monoclonal antibody or antigen binding fragment of claim 2 , and one or more anti-CD3 antibodies.

11. A composition comprising the antigen binding fragment of claim 3 , and one or more anti-CD3 antibodies.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2013
From: HERCEND, THIERRY; TRIEBEL, FREDERIC; ROMAN-ROMAN, SERGIO
To: AVENTIS PHARMA S.A.
Reel/Frame 030867/0543 →
Priority Claims (2)
FR 91/01613 · Feb 12, 1991 · national
FR 91/04523 · Apr 12, 1991 · national
Continuity (6)
Division 10095672 · Mar 12, 2002
Continuation 09103460 · Jun 24, 1998
Division 08437353 · May 9, 1995
Division 08423383 · Apr 14, 1995
Continuation 07934530 · Nov 23, 1992
Related Publication 20080069770A1 · Mar 20, 2008